On Thursday, UniQure stock experienced a significant decrease following news that the FDA has stated insufficient evidence for the approval of their Huntington's gene therapy. The rejection from the FDA has caused another drop in UniQure's stock, indicating a challenging situation for the company. This news emphasizes the uncertainty surrounding the fate of UniQure's treatment for Huntington's disease.